Lowering Drug Costs for American Families Act
- Last Action
- 12/17/2024
Actions
- 2024-12-17Referred to the Subcommittee on Health.
- 2023-07-28Referred to the Subcommittee on Health.
- 2023-07-26Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and the Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2023-07-26Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and the Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2023-07-26Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and the Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2023-07-26Introduced in House
- 2023-07-26Introduced in House
CRS Summary
As of 2023-07-26 (00)
Lowering Drug Costs for American Families Act
This bill expands the Medicare Drug Price Negotiation Program to include additional drugs and drugs that are covered under private insurance. It also extends certain rebate requirements for covered drugs under Medicare to drugs that are covered under private insurance.
Current law requires the Centers for Medicare & Medicaid Services (CMS) to negotiate maximum prices for brand-name drugs that do not have other generic equivalents and that account for the greatest Medicare spending; the CMS must eventually negotiate the prices of 20 drugs that are covered under Medicare in 2029 and each year thereafter.
The bill requires the CMS to negotiate the prices of 50 drugs beginning in 2029. It also applies the negotiated maximum prices under the program to drugs that are covered under private health insurance, unless the insurer opts out. The CMS, Department of Labor, and Department of Treasury must publish a list of insurers that choose to opt out; insurers must also publicly disclose their decision to opt out.
Current law also requires drug manufacturers to issue rebates to the CMS for brand-name drugs without generic equivalents under Medicare that cost $100 or more per year per individual and for which prices increase faster than inflation. The bill extends these requirements to drugs that are covered under private insurance.
Cosponsors (20)
- RICHARD NEAL (D-MA)
- Robert Scott (D-VA)
- MIKE THOMPSON (D-CA)
- Henry Johnson (D-GA)
- Jamie Raskin (D-MD)
- Steve Cohen (D-TN)
- ELEANOR NORTON (D-DC)
- Haley Stevens (D-MI)
- KWEISI MFUME (D-MD)
- Kathy Castor (D-FL)
- Joe Courtney (D-CT)
- Paul Tonko (D-NY)
- Susan Wild (D-PA)
- David Trone (D-MD)
- Robert Garcia (D-CA)
- Robin Kelly (D-IL)
- Elissa Slotkin (D-MI)
- Dina Titus (D-NV)
- Sheila Cherfilus-McCormick (D-FL)
- Lois Frankel (D-FL)
Subjects
- Government information and archives
- Health care costs and insurance
- Medicare
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.